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Abstract: Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring
dopamine metabolites or alpha-synuclein in cerebrospinal fluid. However, these markers do not
allow early detection, precise prognosis or monitoring of disease progression. Moreover, PD is
now considered a multifactorial disease, which requires a more precise diagnosis and personalized
medication to obtain optimal outcome. In recent years, advanced metabolite profiling of body fluids
like serum/plasma, CSF or urine, known as “metabolomics”, has become a powerful and promising
tool to identify novel biomarkers or “metabolic fingerprints” characteristic for PD at various stages of
disease. In this review, we discuss metabolite profiling in clinical and experimental PD. We briefly
review the use of different analytical platforms and methodologies and discuss the obtained results,
the involved metabolic pathways, the potential as a biomarker and the significance of understanding
the pathophysiology of PD. Many of the studies report alterations in alanine, branched-chain amino
acids and fatty acid metabolism, all pointing to mitochondrial dysfunction in PD. Aromatic amino
acids (phenylalanine, tyrosine, tryptophan) and purine metabolism (uric acid) are also altered in most
metabolite profiling studies in PD.
Keywords: biomarker; metabolite profiling; metabolomics; Parkinson’s disease
1. Introduction
Parkinson’s disease (PD) is a common, age-related progressive neurodegenerative disease, affecting
more than 1% of the population over 60 years of age [1]. Diagnosis of PD relies on clinical history,
physical examination and the response to dopaminergic drugs, but misdiagnosis is common in early
phases of the disease [2]. Clinical symptoms, such as hypokinesia, tremor at rest, rigidity and/or postural
instability first appear after patients have lost about 80% of dopaminergic nerve terminals in the striatum
as assessed in vivo using SPECT or PET imaging for the dopamine transporter (DAT) [3,4] or lost 30–50%
of dopaminergic cell bodies in substantia nigra as assessed post-mortem [5]. In the prodromal phase of
PD where motor symptoms are not yet apparent patients may suffer from hyposmia, rapid eye movement
(REM) sleep behavior disorder, depression and/or constipation [6,7]. Dopaminergic changes observed
on DAT scans appear relatively late in the disease process. Moreover, DAT scans cannot differentiate
PD from multi-system atrophy (MSA), progressive supranuclear palsy (PSP) or other neurological or
neurotoxic disorders associated with severe loss of dopaminergic nigrostriatal terminals. The final
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confirmation of the PD diagnosis depends on post-mortem examination of brain tissue for the presence of
alpha-synuclein-containing Lewy bodies and the loss of nigral neurons.
Despite extensive preclinical research in animal models of PD, there are still no effective
neuroprotective or disease-modifying drugs for PD on the market. Thus, current drug treatment for PD
continues to be based on symptomatic, dopamine replacement therapies, in some cases supplemented
with antidyskinetic drugs, such as amantadine [8]. After several years of treatment with L-DOPA and
related drugs, the majority of PD patients develop L-DOPA-induced-dyskinesia (LID), which is a serious,
irreversible adverse reaction to chronic treatment in more advanced stages of PD [9]. At present, it is not
possible to predict which PD patients are at risk of developing LID.
PD is a multifactorial disorder where genetic factors, environmental exposures and aging contribute
to the risk of developing the disease. There is a large variability in the onset and course of the
disease. In both sporadic and genetic PD, the underlying pathophysiological and pathogenetic
mechanisms include mitochondrial dysfunction, oxidative stress, Lewy body pathology (alpha-synuclein
aggregation) and deficits in proteasomal function or autophagy-lysosomal degradation of defective
proteins (e.g., alpha-synuclein) [10–13]. The majority of PD cases have no known monogenetic etiology,
but a subset of cases is associated with mutations in alpha-synuclein, LRRK2, Parkin, PINK1, DJ-1 [14,15]
or glucocerebrosidase (GBA) and other lysosomal enzymes [16–20].
After the discovery of the key roles of alpha-synuclein in Lewy body pathology in PD and
related disorders (MSA, PSP) and tau, phosphorylated-tau and amyloid-beta (1-42) in neurofibrillary
tangles and plaques in Alzheimer’s disease (AD), major research efforts have been directed to the
measurements of these proteins in body fluids, particularly in CSF. In the Parkinson’s Progression
Markers Initiative study, these markers were measured in a large cohort study of patients with
newly-diagnosed PD, but the diagnostic and prognostic value of these markers was limited due to
large overlap between healthy controls and early PD [21]. In this study, the level of alpha-synuclein was
lower in PD patients with the non-tremor dominant phenotype, compared with the tremor-dominant
phenotype. Another longitudinal study of CSF alpha-synuclein observed increases of alpha-synuclein
over two years in patients with a long disease duration, but not in patients with a short disease
duration [22], further complicating the use of alpha-synuclein as a diagnostic and prognostic marker.
Changes in CSF amyloid-beta (1-42) and tau have been related to cognitive decline in PD, but only in
combination with information on age of onset, non-motor assessments and DAT imaging do these CSF
markers have a predictive value [23].
Although much progress has been made in PD biomarker research as illustrated by the work cited
above, clinically useful biochemical markers remain to be identified and validated for early and more
precise diagnosis of PD or for differentiation of subtypes of PD, which may require different treatments.
Biomarkers are also needed to predict the course of the disease including possible adverse effects of
dopamine replacement strategies, the development of LID and to monitor the effect of experimental
disease-modifying treatments in the future. Since PD is now considered to be a diverse group of
disorders, rather than a single pathogenic disease entity, affecting both the peripheral and central
nervous system [7,24], it has been suggested that precision medicine applied to PD should be based on
biomarker profiles instead of clinical features, which can change rapidly within a few years and which
overlap to a large extent [25].
2. Metabolites as Biomarkers
Before the discovery of genetic forms of PD and the development of sensitive assays to
detect proteins associated with PD pathology in body fluids, biomarker studies for PD focused
on changes in small molecules/metabolites (mainly in CSF), such as catecholamines, serotonin, amino
acids (including neurotransmitters like GABA, glycine, glutamate or precursors of the monoamine
neurotransmitters including phenylalanine, tyrosine, tryptophan and related compounds) using HPLC
with electrochemical, fluorescent or UV detection. Other small molecules of interest are glutathione
and purine metabolites, including uric acid, because of their role as antioxidants [26–28].
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For original articles on catecholamines and metabolites as biomarkers in PD, we refer to [29–31] and
for recent reviews [32–34]. Loss of catecholamines and their metabolites in PD biofluids can only reliably be
detected in drug-naive patients or after long-term drug (L-DOPA) wash-out. Furthermore, CSF levels of the
dopamine (DA) metabolite homovanillic acid (HVA) appear to be a less reliable marker for loss of central
DA than CSF levels of the other DA metabolite, dihydroxyphenylacetic acid (DOPAC), which shows high
accuracy in separating PD patients, including recently-diagnosed patients, from controls [29–31].
Changes in CSF amino acids assessed by conventional HPLC techniques have been extensively
reviewed [34,35]. The various results obtained for CSF amino acids levels in PD do not allow firm
conclusions regarding which pathways are affected in PD. The lack of consistent results may be due
to the lack of adequate matching of cases and controls, differences in anti-Parkinson therapy, which is
a major confounding factor, and differences in storage and processing of samples. Amino acid metabolism
in PD has also been studied by more recent metabolomic approaches using nuclear magnetic resonance
(NMR) and liquid chromatography-mass spectrometry (LC-MS). Results obtained in clinical studies of
body fluids are summarized in Table 1 and results of experimental studies in Table 2.
Proton (1H) and phosphorus (31P) magnetic resonance spectroscopy (MRS) are noninvasive
imaging techniques that have been used to the study metabolites involved in energy metabolism
(e.g., lactate, creatine, phosphocreatine, ATP) and other abundant metabolites (e.g., N-acetylaspartate,
a neuronal marker or choline-containing compounds) in vivo in brain tissues. Some 1HMRS studies
reported elevations of striatal lactate in PD or animal models of PD [36,37], but most studies report
a reduction of N-acetylaspartate/creatine or N-acetylaspartate/choline ratios in advanced, but not in
early PD [38–41].
In the next sections, we discuss the methodology and analytical platforms used in metabolomic
studies and summarize the major findings of metabolite profiling studies in PD.
3. Metabolomics in PD
In diabetes and cancer research, metabolic profiling has played a major role in uncovering specific
metabolic pathways associated with disease processes and characterizing subtypes of, e.g., prostate or
breast cancer [42]. We are not yet at this stage in PD metabolite profiling research. The aim of metabolic
studies in PD is to identify candidate biomarkers or, more likely, provide a metabolic fingerprint for
early diagnosis and prognosis, monitoring disease progression and the effect of disease-modifying
treatments, as well as to gain a better understanding of the molecular pathogenesis of PD or its
various genetic and/or sporadic subtypes. Metabolic profiling of tissues or biofluids reflects the
complex interaction of genes, proteins and the internal and external environment of an individual.
Differences between metabolic profiles of individuals or groups of healthy or diseased persons can be
the result of differences in genetic background, epigenetic modifications, lifestyle, stress, pathogen
exposure, diet, medication, gut flora, and so on. The first metabolomic studies in neurodegenerative
diseases, including PD and Alzheimer’s disease (AD) have been reviewed by various authors [43–46].
3.1. Analytical Challenges to Assess the “Metabolome”
Recent developments in analytical chemistry, especially liquid chromatography-mass
spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) and the availability
of extensive software tools for analyzing big data allow the detection, identification and quantification
of very large numbers of molecules in the micro- and nano-molar range in body fluids, such as
CSF, blood and urine. Metabolomics refers to the study of the entire complement of metabolites
(or small molecules) in a biological system: the “metabolome” [47]. The genome, transcriptome
and proteome, where the basic analyte molecular structure is made up by polymers based on four
nucleotides or 20 encoded and additional derived amino acids can be subjected to in-depth analysis
using a single instrumental setup, respectively. The metabolome, however, is much more chemically
diverse, and thus, multiple approaches involving different extraction and analytical methods must be
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applied to obtain unbiased and complete information about the entire metabolome (see the reviews on
this topic [48,49]).
3.2. Sample Preparation, Extraction Procedures and Analytical Platforms
The extraction methods in metabolomics-driven PD research (regardless of sample type) consist
primarily of protein removal by precipitation in organic solvent and centrifugation (e.g., [50–52]) or by
centrifugal filtration prior to lyophilization. Samples for GC-MS are derivatized to increase volatility
and thermal stability before sample injection and analysis [50,53,54]. Samples for LC-MS, NMR or the
liquid chromatography electrochemistry array (LCECA) are typically resuspended in a small volume
of analysis-friendly solvent (containing deuterium for NMR) before injection (e.g., [51,55,56]).
The analytical platforms can be divided into at least four groups: LCECA, NMR, GC-MS
and LC-MS, which have been excellently reviewed [49,57,58]. In brief, LCECA contains multiple
coulometric electrodes in an array allowing detection and quantification of compounds as a function of
their retention times and oxidation-reduction potentials [59,60]. This method has very high sensitivity
and reproducibility, but relatively low throughput due to longer run times (e.g., 110 min [51,56]) of
consecutive samples and yields no structural information. NMR is based on atom-centered interactions
and can provide high level structural information (reviewed in [61]). In GC-MS, the compounds are
typically derivatized and then separated in the gas-phase on a long column before mass spectrometric
analysis (mass over charge separation). In LC-MS, the analytes are separated in solution and ionized
before analysis in the MS (see [62] for an excellent book on mass spectrometry). NMR, GC-MS and
LC-MS are frequently used for metabolomics (see Table 1) as they provide structural information,
have high throughput and can analyze a large variety and mixtures of compounds. The main
advantage of NMR is the ability to identify novel compounds where the MS-based approaches need
reference information in order to identify a compound. On the other hand, the sensitivity of NMR is
several orders of magnitude lower than the sensitivity of GC-MS and LC-MS [49,63]. Compounds in
the nM range cannot be detected by NMR, as too large volumes would be needed, and thus, the
MS-based approaches are preferred to detect and quantify compounds in this nM range, which is
also apparent from Table 1. However, pre-analytical enrichment procedures can be needed also for
LC-MS (or LCECA) to measure compounds in the low nM range (e.g., catecholamines in plasma or
CSF) [31,64]. NMR can detect water-soluble protonable species, whereas LC-MS and GC-MS provide
a much broader profile of compounds, which, however, can only be identified with access to reference
information. GC-MS is most suitable for less polar and volatile compounds, whereas LC-MS allows
detection of an even broader profile of metabolites and is generally preferred for the more polar
compounds, all depending on the setup (discussed in [58,65]). To get a profile as broad as possible,
the samples are often analyzed with both GC-MS and LC-MS, where the latter is used in both negative
and positive ion mode, which favors acidic and basic compounds, respectively (e.g., [53,66,67]).
The analytical platforms needed for comprehensive metabolite profiling are quite expensive,
and most laboratories cannot afford to acquire them all. Thus, research groups should choose the
most appropriate instrument based on the chemical characteristics and abundance of the compounds
of interest.
3.3. Identification and Quantification of Small Molecules
When no synthetic reference standard is available, the identification of compounds is a major
challenge in non-NMR-based metabolomics. Reports on the level of confidence in the identification
of compounds have been inconsistent, and thus, The Metabolomics Standards Initiative (MSI)
was launched 10 years ago, and more recently, the Coordination of Standards in Metabolomics
(COSMOS) was initiated [68]. Summer et al. [69] reported that confident identification should be
based on a minimum of two pieces of information related to a reference standard (e.g., retention time,
fragment ions and accurate mass), whereas less confident identification should only be referred to as
putatively-annotated compounds or unknowns. In untargeted MS-based metabolomics, a large part
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of the extracted compounds comprises unknowns or only putatively identified ones (e.g., [70–72]).
Challenges in the identification of small molecules using LC-MS have been described elsewhere [63,73].
To allow quantitative comparison with the literature (e.g., to compare control groups in different
studies) or to compare the quantity of different compounds, absolute quantification is required.
This requires inclusion of standards of known amounts and is thus most commonly only used in
targeted metabolomics. External standards are used in LCECA, whereas internal isotope-labelled
standards are optimal for absolute quantification in MS and NMR. In MS, the signal intensity is not
only dependent on the ion amount, but also very much on the chemical structure of the analytes and
on the sample matrix (potentially causing signal suppression). Thus, an isotope-labelled standard is
required for absolute quantification of the individual compound as has been demonstrated for a few
compounds in Havelund et al. [52]. Metabolite quantification has been reviewed for NMR [74] and for
MS-based metabolomics [75].
3.4. Untargeted versus Targeted Analysis at Acquisition or Data Analysis Levels
The mass spectrometry-based analysis in the PD-related studies reviewed here (Table 1) is performed
as untargeted at the analytical level, without pre-selection of compounds for fragmentation. Some of
the LC-MS-based approaches use MS/MS with data-dependent acquisition (DDA), only fragmenting
the most intense ions in a spectrum [53,66,71], whereas others run the samples again after the statistical
analysis in a targeted analytical setup only focusing on the identification of the statistically interesting
compounds [67,70,72,76]. In the GC-MS studies, MS/MS is not utilized, as fragmentation already is
induced by the use of electron ionization (EI). Not only the data acquisition, but also the data analysis
may be regarded as targeted or untargeted. In the latter case, all compounds (typically more than 500) are
extracted and aligned automatically using different specific settings and thresholds. Some low abundant
or bad peak shape compounds might thus not be extracted in the subsequent statistical analysis. In the
targeted analysis, however, only a subset of compounds (e.g., the identified analytes) is used in the data
analysis, allowing manual inspection of all peaks and correction of miss- or non-assigned peaks. Targeted
and untargeted metabolomics have been reviewed in [77].
3.5. Statistical Analysis
Multivariate statistics such as principal component analysis (PCA) or partial least squares
discriminant analysis (PLS-DA) are often used to generate metabolic fingerprints or to find the
compounds most responsible for group separation, especially in untargeted (or large-scale targeted)
metabolomics [50,51,54,71,76]. Hereby, the relative differences in the metabolomes of different groups
(e.g., PD versus controls or different PD subgroups) are determined. In brief, PCA is unsupervised,
only showing group separation when within-group variation is sufficiently less than between-group
variation and, thus, often fails to separate the groups of interest [50,71]. The supervised approaches like
PLS-DA rely on class membership of each observation and overfit models to the data, which most
often results in a clear group separation. However, care must be taken as group separation can
be achieved with random data [78]. Therefore, results from supervised statistics must always be
validated [79] and combined with univariate statistics (references from Table 1). Validation is often
lacking in PD-based metabolomic research [50,51,54], possibly contributing to the high degree of variation
of PD metabolomics data. Multivariate statistics in metabolomics have been excellently reviewed
elsewhere [78]. The performance of a biomarker in terms of specificity and sensitivity can be evaluated
using receiver operator characteristic (ROC) curves (reviewed in [80] and applied in [53,67]), a method
widely considered the most objective and valid for this purpose [81–84].
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4. Metabolomics Studies in PD Patients and Experimental Models
4.1. Metabolomic Studies in PD Patients (Table 1)
In Table 1, we have summarized the main findings of metabolite profiling studies in PD over the
last decade. We have found only 15 clinical studies using “metabolomics” or “metabolite profiling”
to identify biomarkers for PD. It has been suggested that metabolomics studies should include at
least 20 patients per group (disease versus control) [85], which is the case for most of the studies in
Table 1. However, in the studies of [52,66], less controls were available, and comparison of subgroups
of PD (e.g., LRRK2 mutations) in [51,52] (patients with and without LID) resulted also in lower
numbers per group. Ultimately, the number of patient and control samples required is an interplay
between analytical variation and the number of data points (metabolites) obtained. The patients
(or controls) were either (a) fasting overnight and unmedicated/withdrawn from medication [71,86],
(b) fasting and on medication [52,66,67,71,72,76], (c) not fasting and unmedicated/withdrawn from
medication [55,56,70,87] or (d) not fasting and on medication [51,56,87]. In some studies, only blood,
CSF or urine was analyzed, whereas in other studies, both serum and urine or CSF and plasma were
analyzed. Combined analyses of different biofluids from the same patients in the same study are
more useful, as some changes may be present in CSF, showing disturbances of metabolites that may
affect brain function or may be altered because of a localized brain lesion, but not in plasma or urine,
which reflect overall body metabolism. Some compounds can easily cross the blood brain barrier and
enter the CSF, whereas other compounds do not. On the other hand, most metabolites, including
brain-derived metabolites such as HVA or N-acetylaspartate, are more abundant in urine (at least
a factor of 10) as compared to blood or CSF [88] and may therefore provide a more reliable metabolic
index of a disease process than fluctuating CSF or plasma levels.
In the studies listed in Table 1, different metabolic profiles were detected between controls
and PD or subgroups of PD, but many of the compounds separating PD from controls [50,56] or
PD-LRRK2 from other PD cases [51] were not structurally identified. Employing metabolomics
and pathway enrichment tools, changes were found in purine metabolism [51,86], oxidative
stress/redox homeostasis [53,56,66], energy metabolism (glycolysis and TCA cycle) [54,55,72], fatty acid
metabolism [54,71,76,86], branched chain amino acids (leucine, isoleucine, valine) [54,72], phenylalanine
and tyrosine metabolism [66,67,76,86], tryptophan metabolism [53,54,66,67,76], glycine derivation
(related to FA metabolism) and steroidogenesis [67,76]. Correlations with the progression of PD were
found for changes in phenylalanine, purine and FA metabolism, serine [86], polyamines [70] and
tryptophan metabolism via the kynurenine pathway in urine [67,76], plasma and CSF [52].
Some studies reported no effect of L-DOPA/peripheral decarboxylase inhibitor treatment in
metabolic profiling [50], but there are profound metabolic effects of this type of treatment on aromatic
amino acid metabolism (tyramine, tryptophan) in plasma, CSF [52] and urine [89,90]. Thus, dopaminergic
drug treatments should be taken into account when metabolite profiles are to be compared between PD
and controls or between various PD subgroups. If samples are used from PD patients on anti-Parkinsonian
medication, including L-DOPA, it is advised to collect the samples within a fixed interval after drug intake.
In this way, medication-induced changes in tyrosine metabolism and related pathways can be studied
and compared between different PD groups, e.g., with and without L-DOPA-induced dyskinesia [52].
The recent study by LeWitt et al. [86] in unmedicated PD patients addressed the question: How
informative is the initial biochemical profile or its change in later collected specimens for predicting
disease progression? The authors concluded that CSF-HVA is a poor predictor of PD progression,
but that several purines (compounds with xanthine structure) and some medium- or long-chain FA
correlated strongly with worsening of Unified Parkinson’s Disease Rating Scale (UPDRS) scores.
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Table 1. Overview of metabolomic studies in PD clinical research. LCECA, liquid chromatography electrochemistry array; LID, L-DOPA-induced-dyskinesia; BCAA,
branched chain amino acid.
Article AnalyticalPlatform
Statistics Patients (#)
Pathway/Compound
Increased in PD Decreased in PD
Bogdanov et al.,
2008 [56] LCECA
PLS-DA
t-test PD (60), controls (25) B: Glutathione metabolism (GSH) B: Purine metabolism (uric acid )
Johansen et al., 2009
[51] LCECA PLS-DA
PD (41), PD-LRRK2 (12),
healthy-LRRK2 (21),
controls (25)
B: Purine metabolism (uric acid, hypoxanthine)
Ahmed et al., 2009
[55] H-NMR
PLS-DA,
ANOVA PD (43), controls (37) B: Energy metabolism (pyruvate) B: Energy metabolism (TCA metabolites, creatinine)
Roede et al., 2013
[70] LC-MS
2 + (O)PLS-DA
t-test
PD rapid progress (39),
PD slow progress (41),
Controls (20)
B: Polyamine metabolism (N8-acetylspermidine)
LeWitt et al., 2013
[53]
LC-MS2 +/−
GC-MS
t-test
ROC curve PD (48), controls (57) C: Kynurenine metabolism (3-HK/KYNA)
C: Acetylated amino acids, C: glutathione
metabolism (GSSG)
Trupp et al.,
2014 [54] GC-MS (O)PLS-DA PD (20), controls (20)
B: Amino acids (methionine, threonine,
alanine, serine), glutathione metabolism
(pyroglutamate), ketoleucine
C: Energy metabolism (creatinine), tryptophan
metabolism (tryptophan)
B: FA metabolism (C16 and C18)
Öhman and
Forsgren 2015 [87]
H-NMR Multivariate,univariate PD (10), controls (10)
C: Amino acids (alanine), energy metabolism
(creatinine), sugars (mannose)
Luan et al., 2015 [67] LC-MS +/− (O)PLS-DAROC curve PD (106), controls (104) U: BCAA, Glycine derivatives, histidine metabolism,
tryptophan/kynurenine metabolism, phenylalanine
metabolism , purine metabolism, steroidogenesisLuan et al., 2015 [76] LC-MS
+/−
GC-MS
(O)PLS-DA PD (92), controls (65)
Hatano et al.,
2016 [66]
LC-MS +/−
GC-MS
t-test PD (35), controls (15) U: Phenylalanine metabolism (phenylacetate) B: Bilirubin/biliverdin, tryptophan metabolism
Wuolikainen et al.,
2016 [72]
LC-MS +/−
GC-MS
(O)PLS-DA PD (22), ALS (22), controls(28)
B and C: Amino acids (alanine)
C: BCAA (leucine, isoleucine)
LeWitt et al.,
2017 [86]
LC-MS +/−
GC-MS
Multivariate
t-test
PD (49); collected twice
with an interval of up to 2
years
B: FA metabolism (medium-long chain FA),
phenylalanine metabolism (aspartylphenylalanine,
benzoate), serine metabolism (serine)
B: Purine metabolism (inosine)
Burté et al., 2017 [71] LC-MS
2 +/−
GC-MS
PCA
(O)PLS-DA
PD early stage (41),
Controls (40)
B: FA metabolism (acylcarnitine), histidine
metabolism (1-methylhistamine)
Havelund et al.,
2017 [52] LC-MS
+ ANOVA PD (26), PD-LID (10),controls (14) B: Kynurenine metabolism (3-HK/KYNA) B and C: Kynurenine metabolism (anthranilic acid )
2 Data-dependent MS/MS; +/− shows which MS ion mode was used; B/C/U: indicate in which biofluid (B: blood, C: CSF, U: urine) the compound/pathway was found.
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Table 2. Overview of metabolomic studies in PD model organisms. DOPAC, dihydroxyphenylacetic acid.
Article AnalyticalPlatform
Statistics Model (Treatment) Tissue or Cells
Pathway/Compound
Increased in PD Decreased in PD
Li et al., 2013 [91] LC-MS + PCA, PLS-DA, t-test
Mice (MPTP-treated
mice, Acanthopanax
senticosus harms)
Midbrain
Ceramide (d18:0/18:0),
FA metabolism (lysoPC 20:4),
methionine metabolism
(5-methylthioadenosine),
morphiceptin,
sphingolipid metabolism
(phytosphingosine-1-P),
tetracosanoylglycine,
tyrosine metabolism (L-DOPA)
Poliquin et al.,
2013 [92] LC-MS
+/− Not reported Parkin KO mice(complex I inhibitor) Brain slices Energy metabolism (ATP)
Lei et al., 2014 [93] H-NMRMS PLS-DA, ANOVA
Neuroblastoma cells
(6-OHDA, MPP+,
rotenone, or paraquat)
Cells
Energy metabolism (pentose phosphate
pathway),
sugars (heptose, hexose)
Energy metabolism (TCA cycle),
amino acid (glutamate),
tyrosine metabolism (dopamine)
Lu et al., 2014 [94] H-NMRLC-MS +/−
PCA, OPLS-DA,
t-test,
Mann−Whitney
U-test
Goldfish
(MPTP-treated) Whole brain
Alanine metabolism (alanine, alanylalanine),
amino acids (taurine),
BCAA (leucine, isoleucine, valine),
energy metabolism (creatinine),
FA metabolism (18:2, total FA),
sugars (myo-inositol, a glial marker)
Energy metabolism (TCA metabolites),
FA metabolism (n-3 FA, unsaturated FA),
glutamine metabolism,
neuronal injury markers,
tyrosine metabolism (dopamine, DOPAC)
Chen et al.,
2015 [95]
LC-MS2 +/−
GC-MS
PCA, ANOVA,
Random forest
Mice (alpha-syn A53T
transgenic) Forebrain and midbrain
Alanine metabolism,
acetyl-CoA biosynthesis pathways Purine metabolism (guanosine)
Farmer et al.,
2015 [96] LC-MS
2 + t-test Rats (6-OHDA) Substantia nigra Lysophosphatidylcholine (C16:0, 18:1) Lysophosphatidylcholine,phosphatidylcholine species (12 species)
Tyurina et al.,
2015 [97] LC-MS
− Rats (rotenone) Substantia nigra (SN)Blood (B)
SN: Mono-oxygenated cardiolipin
metabolism,
B: Polyunsaturated FA cardiolipin
SN : unsaturated FA cardiolipin species
Luan et al.,
2015 [67] LC-MS
+ Mann−Whitney
U-test
Drosophila (alpha-syn
overexpressing) Whole flies
Kynurenine metabolism
(kynurenine/KYNA)
Shukla et al.,
2016 [98]
LCECA
GC-MS t-test Drosophila (paraquat) Fly heads
Alanine metabolism (alanine),
energy metabolism (lactate acid),
FA metabolism (hexadecanoic acid, oleic
acid),
glycerolipid metabolism,
glycine metabolism (glycine),
sugars (inositol, myo-inositol)
Amino acids (γ-aminobutyric acid, proline),
BCAA (isoleucine, leucine, valine),
purine metabolism (uric acid),
sugars (glucose, galactose, trehalose),
tyrosine metabolism (dopamine)
2 Data-dependent MS/MS, +/− show which MS ion mode was used.
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4.2. Metabolomic Studies in Experimental Models of PD (Table 2)
The advantages and disadvantages of both toxic and genetic animal models of PD have been
extensively reviewed by various authors [9,99–102]. Animal models of PD have been used to study markers
of dopaminergic degeneration, changes in receptors or alteration in blood flow or energy consumption
using PET or NMR imaging [103]. In vitro models of PD include cell and slice culture models [104] and
most recently also differentiated neurons from human iPS cells [105,106]. However, only a few experimental
studies used a metabolomic approach to identify novel biomarkers of PD. We have summarized these
studies in Table 2.
Table 2 includes one in vitro model, i.e., neuroblastoma cells treated with different toxins [93],
the MPTP mouse model [91], Parkin knock-out mice [92], transgenic alpha-syn A53T mice [95],
a 6-hydroxydopamine-lesioned rat model [96], a rotenone-treated rat model [97], an MPTP–treated
goldfish model [94] and alpha-synuclein overexpressing Drosophila [76] or paraquat-treated fruit
flies [98]. In all animal studies, metabolite profiles were assessed in brain tissues and in the vitro study
in cell extracts and culture medium. Thus, a comparison with human studies where metabolites are
usually determined in CSF, plasma or urine is not necessarily feasible.
In Parkin knock-out mice [92], no differences were found in ATP or energy-related metabolites,
whereas treatment with the mitochondrial uncoupler CCCP caused a marked drop in ATP. Apparently,
in Parkin KO mice, mitochondrial function is not impaired to a degree that causes changes in TCA
intermediates or other compounds related to energy metabolism.
In the study using transgenic A53T and wildtype mice [95], not only the effect of the genotype,
but also age-related changes were studied in wildtype and transgenic mice. The study reported
an interaction between aging and genotype on guanosine levels (purine metabolism), whereas changes
in alanine, glutathione and acetyl-CoA metabolism were age-related in both wildtype and Tg mice.
A change in purine metabolism (reduced uric acid) was also observed in the paraquat fly model [98].
Changes in energy metabolism were observed in the MPTP mouse [91], neuroblastoma cell cultures
treated with toxins [93], MPTP-treated goldfish [94] and paraquat-treated flies [98]. Changes in FA
metabolism were reported in different animal models using mitochondrial toxins, including the
MPTP mouse [91], MPTP-treated goldfish [94] and rotenone-treated rats [97]. Branched chain amino
acid (BCAA) metabolism was altered in the MPTP-treated goldfish [94] (BCAA levels increased)
and paraquat-treated flies [98] (BCAA levels decreased). Tyrosine metabolism was altered in
the MPTP mouse [91], and tryptophan metabolism (increased KYN/KYNA ratio) was affected in
alpha-syn-overexpressing flies [76].
In conclusion, metabolite profiling in brain tissues of different animal models listed in Table 2 revealed
changes in some of the pathways identified in the clinical studies of Table 1. However, the potential of
using animal studies of PD for longitudinal metabolic profiling in CSF, plasma, urine and brain tissues is
not fully explored. In addition, the effects of chronic drug treatments (e.g., L-DOPA) and the relationship
between changes in metabolite profiles in brain tissue and various body fluids, CSF, plasma and urine
still require further studies.
5. General Discussion
Both clinical (Table 1) and experimental studies (Table 2) have consistently shown alterations
in alanine metabolism, branched chain amino acids (BCAA) metabolism, FA metabolism and
steroidogenesis, all pointing to mitochondrial dysfunction in PD. BCAAs are transported into the
brain via the large neutral amino acid transporter [107]. Since aromatic amino acids (tryptophan,
phenylalanine, tyrosine, but also L-DOPA) use the same transporter, L-DOPA treatment of PD patients
may interfere with BCAA plasma levels. We are not aware of clinical or experimental biomarker
studies that have addressed the relationship between chronic L-DOPA use and circulating BCAA
levels. An elevation in BCAAs (leucine, isoleucine, valine) has also been associated with mitochondrial
respiratory chain disease [108], insulin resistance and the development of type 2 diabetes [109,110].
In Alzheimer’s disease (AD) [111] and in patients with pyruvate dehydrogenase deficiency [108], serum
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levels of valine are decreased, but in a mouse model of AD BCAA levels, including valine, they were
reported to be increased [112]. BCAA plays an important role in bioenergetics, protein synthesis
and mitochondrial biogenesis. In addition, BCAA regulates macroautophagy (and mitophagy) by
activating mammalian target of rapamycin complex 1 (mTORC1) [113]. Activation of mTORC1
inhibits macroautophagy, whereas inhibition of mTORC1 by rapamycin or other means can provide
neuroprotection in animal models of PD [114,115] and attenuate L-DOPA–induced dyskinesia in
6-OHDA lesioned rodents [116,117]. Changes in concentrations or abundance (up and down) of
related metabolites can be expressed as ratios. Accordingly, in mitochondrial disease, alterations in
the ratios of alanine to glutamate, BCAA to glutamate or lactate to pyruvate have been reported [108].
We propose to look at such ratios at the individual patient level in PD metabolite profiling studies.
An accumulation of free fatty acid in plasma or alterations in brain tissue (up- or down-regulations)
has been reported in PD (Table 1) and experimental models of PD (Table 2). Such changes are also observed
in disorders associated with mitochondrial dysfunction [118]. Alterations of phosphatidylcholine and
lysophosphatidylcholine lipids may not only point to mitochondrial dysfunction and/or neuronal cell
loss, but may also play a role in pro-apoptotic or anti-apoptotic signaling [96].
Several metabolomics studies listed in Tables 1 and 2 identified decreased purine metabolism in
PD or models of PD. The end product of purine metabolism, uric acid, is a scavenger of reactive oxygen
and reactive nitrogen species and may thus reduce oxidative/nitrative stress. Low uric acid levels
have been associated with PD and increased progression of disease in epidemiological studies [26,119].
In contrast, dietary intake of caffeine, a xanthine (purine) compound, has been associated with reduced
risk of PD and reduced risk of developing L-DOPA-induced dyskinesia [120,121].
Global metabolite changes in body fluids may reflect a (neuro)pathological process (e.g., mitochondrial
dysfunction, inflammation or deficits in autophagy-lysosomal function), but do not localize the damage to
specific brain circuits or neuronal cell types. Neurological and psychiatric symptoms (and the diagnosis
of a specific disease entity) are highly dependent on which brain regions, neuronal circuitries, cell types
or transmitter systems are affected by the disease. Thus, the neurochemical characteristics of the patients
should be taken into account in conjunction with more global metabolic disturbances, such as changes in
FA metabolism or BCAA.
A myriad of small molecules related to amino acid and/or FA metabolism, such as kynurenine
metabolites [122], glycine, serine [123], n-acetylated amino acids or endocannabinoids [124], act as
neuromodulators on, e.g., receptor-ion-channel complexes (e.g., NMDA, nicotine ACh receptors), G protein
coupled receptors, voltage-gated calcium channels or glycine transporters. Disturbances of the metabolism
of these neuromodulators or alterations in the ratios of neuroactive metabolites may contribute to
neurological and psychiatric diseases. Alterations in kynurenine (KYN) metabolism, which may give rise
to either neurotoxic compounds such as 3-hydrokynurenine (3-HK) or neuroprotective/neuromodulating
compounds like kynurenic acid (KYNA), are often expressed as ratios 3-HK/KYNA [52,53] or
KYN/KYNA [76] and indicate whether the neurotoxic or neuro-modulating branch of the KYN pathway
is favored in the individual patient. Thus, metabolite profiling of body fluids in PD and other brain
diseases should also focus on low abundance (nM range) small molecules known to act as neuromodulators,
since abnormalities in such compounds can potentially be treated with specific enzyme inhibitors.
6. Conclusions and Future Perspectives
Metabolite profiling of body fluids of PD patients or patients at risk developing PD (e.g., REM
sleep disorders) is a powerful tool to identify novel biomarkers for early diagnosis, prognosis and
monitoring of disease progression. In Figure 1, we summarized the metabolic pathways and related
metabolites showing alterations in PD based on the current literature. However, still much validation
work and improvement of procedures are needed before metabolite profiling can be implemented in
the clinic. Anti-Parkinson medication, in particular L-DOPA treatment, is a major confounding factor
in metabolite profiling studies, and care should be taken to collect biofluid samples at fixed time points
after the intake of medication or after drug-wash-out (if this is ethically possible). The identification and
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quantification of all compounds showing statistical differences between controls and PD patients is still
a major challenge. In future studies, it will be important to confirm the identification and to quantify
the compounds of interest using isotope-labelled standards (those showing differences between PD
and controls) using a targeted approach during data acquisition. Absolute quantification is important
in order to compare results with the literature and to check whether similar levels were detected in
different control groups. From the point of view of analytical laboratories, it is also mandatory to
document procedure variation (inter- and intra-assay), normal ranges and robustness. We recommend
also to collect, if possible, samples from different biofluids from the same patients, (e.g., CSF, plasma,
saliva and urine) in order to study whether altered metabolite profiles in CSF are reflected in plasma,
saliva or urine.
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in the literature are marked in bold. For simplicity, not all intermediates and reversible processes
are shown.
A hot topic in current PD research is the emerging role of the gut flora in the disease process [125].
Case-control studies have shown differences in the composition of gut microbiota between PD patients
and age-matched controls [126–128], and in addition to changes in certain gut bacteria, one study
reported reductions in fecal short chain fatty acids (acetate, propionate, butyrate) [129]. Alterations in
the gut microbiome also have effects on drug metabolism, and vice versa, chronic drug treatment may
affect the composition of the gut microbiota [130]. In a recent experimental study [131], it was shown
that colonization of alpha-synuclein-overexpressing mice with microbiota from PD-affected patients
enhances physical impairment compared to mice with microbiota transplants from healthy human
donors. Such an approach could also be used to study differences in metabolite profiles in plasma and
urine of wildtype or transgenic mice (or rats) transplanted with gut microbiota from PD patients and
from healthy controls.
It has been suggested that precision medicine applied to PD should be based on biomarker
profiles instead of clinical features or at least on a combination of the clinical features and molecular
profiling. Future advanced metabolomics studies in PD and related disorders will be directed toward
answering the question of whether differences in metabolic profiles can be used to stratify patients into
different therapeutic regimens. This will, however, also require a further understanding of underlying
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disease mechanisms and the identification of novel drug targets, as well as fully-documented and
validated methods.
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